Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ASND
stocks logo

ASND

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
246.16M
+41.54%
-0.173
-72.92%
282.79M
+180.12%
0.393
-124.84%
314.82M
+99.2%
0.657
-202.73%
Estimates Revision
The market is revising Downward the revenue expectations for Ascendis Pharma A/S (ASND) for FY2025, with the revenue forecasts being adjusted by -0.94% over the past three months. During the same period, the stock price has changed by 1.30%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.94%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+27.8%
In Past 3 Month
Stock Price
Go Up
up Image
+1.30%
In Past 3 Month
Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 260.15 USD with a low forecast of 220.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 260.15 USD with a low forecast of 220.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 208.580
sliders
Low
220.00
Averages
260.15
High
325.00
Current: 208.580
sliders
Low
220.00
Averages
260.15
High
325.00
Wolfe Research
Outperform
initiated
$255
2025-11-17
Reason
Wolfe Research
Price Target
$255
2025-11-17
initiated
Outperform
Reason
Wolfe Research initiated coverage of Ascendis Pharma with an Outperform rating and $255 price target. Yorvipath is off to a "strong" launch and "the party is only beginning," according to the analyst, who sees $4B-pluse peak sales "looking increasingly achievable." The stock looks priced as if Yorvipath is the whole story, leaving the derisked pipeline looking "underappreciated," the analyst added.
BofA
Tazeen Ahmad
Buy
maintain
$230 -> $242
2025-10-20
Reason
BofA
Tazeen Ahmad
Price Target
$230 -> $242
2025-10-20
maintain
Buy
Reason
BofA analyst Tazeen Ahmad raised the firm's price target on Ascendis Pharma to $242 from $230 and keeps a Buy rating on the shares. The firm's survey of 26 endocrinologists who treat HPT patients on Yorvipath indicates growing uptake in Q3, says the analyst, who is "encouraged" by the continued positive real-world outlook for Yorvipath usage and looks for updated commentary from the company on payor coverage and trending discontinuation rate on the earnings call.
RBC Capital
Luca Issi
Outperform
maintain
2025-10-20
Reason
RBC Capital
Luca Issi
Price Target
2025-10-20
maintain
Outperform
Reason
RBC Capital analyst Luca Issi says the firm has received a number of inbounds on the Ascendis Pharma stock weakness and a few have pointed out the death reported on the FDA Adverse Event Reporting System database. It looks like the patient passed on August 22nd and that such patient had HER2+ breast cancer and hypoparathyroidism. Initial FDA received date is October 3rd and latest received data was yesterday, the firm notes. This is the first death reported on the FAERS database. RBC thinks this is another reminder that looking at the FAERS database has multiple limitations as it is often difficult to distinguish causation vs correlation. Details are sparse and difficult to be definitive, but the firm believes this is likely an example of the latter given a complex clinical picture, multiple concomitant medications and while the cause of death remains unknown, breast cancer can be fatal. Overall, the firm is not worried about this case and remains a buyer of Outperform-rated Ascendis.
Raymond James
Martin Auster
Strong Buy
initiated
$271
2025-10-16
Reason
Raymond James
Martin Auster
Price Target
$271
2025-10-16
initiated
Strong Buy
Reason
Raymond James analyst Martin Auster initiated coverage of Ascendis Pharma with a Strong Buy rating and $271 price target. The firm sees "a high conviction path" to 2035 total revenues of about $4.6B - including $3.3B for Yorvipath for hypoparathyroidism, $750M for TransCon CNP for achondroplasia and $550M for Skytrofa - as well as "a range of credible upside scenarios," the analyst tells investors.
BofA
Buy
maintain
$227 -> $230
2025-09-02
Reason
BofA
Price Target
$227 -> $230
2025-09-02
maintain
Buy
Reason
BofA raised the firm's price target on Ascendis Pharma to $230 from $227 and keeps a Buy rating on the shares after partner Teijin Limited received manufacturing and marketing approval for Yorvipath in Japan for the treatment of hypoparathyroidism. The firm, which adds the Japan opportunity to its model, maintains a "bullish outlook" on the global Yorvipath opportunity, estimating peak sales of $3.2B.
JPMorgan
Overweight
maintain
$254 -> $260
2025-08-19
Reason
JPMorgan
Price Target
$254 -> $260
2025-08-19
maintain
Overweight
Reason
JPMorgan raised the firm's price target on Ascendis Pharma to $260 from $254 and keeps an Overweight rating on the shares. The firm remains "impressed" by Yorvipath's sales trajectory following the Q2 report. The company sounds confident in Yorvipath's U.S. reimbursement cycle time, the analyst tells investors in a research note. JPMorgan believes Ascendis is at an inflection point with "substantial" operating leverage ahead.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ascendis Pharma A/S (ASND.O) is 98.55, compared to its 5-year average forward P/E of -5.26. For a more detailed relative valuation and DCF analysis to assess Ascendis Pharma A/S 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.26
Current PE
98.55
Overvalued PE
44.86
Undervalued PE
-55.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.76
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
47.19
Undervalued EV/EBITDA
-62.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
122.17
Current PS
0.00
Overvalued PS
347.72
Undervalued PS
-103.38
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 565.41% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ASND News & Events

Events Timeline

(ET)
2025-11-25
18:18:17
Ascendis Pharma Announces FDA Approval Extension for TransCon CN
select
2025-11-17 (ET)
2025-11-17
16:04:11
Ascendis Pharma Releases Findings from ApproaCH Trial in JAMA Pediatrics
select
2025-11-12 (ET)
2025-11-12
16:03:44
Ascendis Pharma announces Q3 EPS of EUR 1.00, up from EUR 0.72 a year ago
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
00:10 AMBarron's
The Biotech Sector Is Stronger Than Investors Realize: Key Stocks to Monitor.
  • Biotech Sector Performance: The State Street SPDR S&P Biotech ETF has shown a poor performance since early 2021, indicating challenges for investors in the biotech sector.
  • Investor Sentiment: The overall trend in the biotech market suggests a significant downturn, leading to a negative outlook for potential investors.
[object Object]
Preview
9.0
11-29Yahoo Finance
Impact of FDA's Delay in Reviewing TransCon CNP at Ascendis Pharma (ASND) on Its Investment Narrative

  • FDA Extension Impact: Ascendis Pharma's TransCon CNP therapy for achondroplasia has had its FDA review date extended to February 28, 2026, which may affect the company's competitive position in the rare disease market.

  • Investment Outlook: The FDA's delay is not expected to significantly impact Ascendis Pharma's short-term investment outlook unless further regulatory issues arise, despite positive trial results supporting the therapy's efficacy.

  • Revenue Projections: Ascendis Pharma is projected to achieve €2.2 billion in revenue and €826.6 million in earnings by 2028, necessitating substantial annual growth, although regulatory delays could negatively affect share prices.

  • Diverse Valuation Estimates: Fair value estimates for Ascendis Pharma's stock vary widely among analysts, ranging from €193 to €738 per share, reflecting differing perspectives on the company's future performance amid ongoing regulatory challenges.

[object Object]
Preview
9.0
11-28Benzinga
Ascendis Pharma Faces FDA Setback as TransCon CNP Decision Postponed to 2026

  • FDA Review Extension: The FDA has extended the review period for Ascendis Pharma's New Drug Application for TransCon CNP (navepegritide) for children with achondroplasia by three months, now targeting a decision by February 28, 2026.

  • Positive Trial Results: Recent results from the ApproaCH Trial indicate that TransCon CNP significantly improved annualized growth velocity and health-related quality of life in children with achondroplasia compared to placebo.

  • Additional Data on TransCon PTH: Ascendis Pharma also reported positive outcomes from a pooled analysis of TransCon PTH in adults with hypoparathyroidism, showing sustained improvements in renal function and a high percentage of patients achieving normocalcemia.

  • Stock Performance: Ascendis Pharma's stock has seen a slight increase, trading at $213.03, reflecting positive investor sentiment following the recent announcements.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ascendis Pharma A/S (ASND) stock price today?

The current price of ASND is 208.58 USD — it has increased 4.03 % in the last trading day.

arrow icon

What is Ascendis Pharma A/S (ASND)'s business?

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

arrow icon

What is the price predicton of ASND Stock?

Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is 260.15 USD with a low forecast of 220.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ascendis Pharma A/S (ASND)'s revenue for the last quarter?

Ascendis Pharma A/S revenue for the last quarter amounts to 213.63M USD, increased 269.40 % YoY.

arrow icon

What is Ascendis Pharma A/S (ASND)'s earnings per share (EPS) for the last quarter?

Ascendis Pharma A/S. EPS for the last quarter amounts to -1.00 USD, decreased -41.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ascendis Pharma A/S (ASND)'s fundamentals?

The market is revising Downward the revenue expectations for Ascendis Pharma A/S (ASND) for FY2025, with the revenue forecasts being adjusted by -0.94% over the past three months. During the same period, the stock price has changed by 1.30%.
arrow icon

How many employees does Ascendis Pharma A/S (ASND). have?

Ascendis Pharma A/S (ASND) has 879 emplpoyees as of December 05 2025.

arrow icon

What is Ascendis Pharma A/S (ASND) market cap?

Today ASND has the market capitalization of 12.87B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free